BBIO250117P25000
- 0.45
- -0.05-10.00%
BridgeBio Pharma Newsroom
BridgeBio Pharma Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $50
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49
BridgeBio Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Receives Buy Rating Following Attruby's FDA Approval and Strategic Milestones
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $55
B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $58
BridgeBio Pharma Analyst Ratings
BridgeBio Pharma's Hold Rating: Balancing Optimism From Acoramidis Approval With Market and Competitive Concerns
BridgeBio Pharma (BBIO) Receives a Buy From Piper Sandler
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $40
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
BridgeBio Pharma (BBIO) Gets a Buy From Scotiabank